Imugene (ASX:IMU) - Share price, News & Analysis

IMU fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

IMU Stock Overview

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia.

Rewards

Revenue is forecast to grow 20.19% per year

Risk Analysis

Earnings are forecast to decline by an average of 1.3% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

Shareholders have been diluted in the past year

Imugene Competitors

Clinuvel Pharmaceuticals

ASX:CUV

AU$761.9m

Telix Pharmaceuticals

ASX:TLX

AU$1.3b

Race Oncology

ASX:RAC

AU$274.4m

Mesoblast

ASX:MSB

AU$636.9m

Price History & Performance

Summary of all time highs, changes and price drops for Imugene
Historical stock prices
Current Share Price	AU$0.20
52 Week High	AU$0.63
52 Week Low	AU$0.15
Beta	2.26
1 Month Change	-13.33%
3 Month Change	-11.36%
1 Year Change	-58.51%
3 Year Change	1,047.06%
5 Year Change	1,400.23%
Change since IPO	100.00%

Shareholder Returns

	IMU	AU Biotechs	AU Market
7D	14.7%	0.5%	-1.2%
1Y	-58.5%	-8.0%	-0.009%

Return vs Industry: IMU underperformed the Australian Biotechs industry which returned -8% over the past year.

Return vs Market: IMU underperformed the Australian Market which returned -0% over the past year.

Price Volatility

Is IMU's price volatile compared to industry and market?
IMU volatility
IMU Average Weekly Movement	13.4%
Biotechs Industry Average Movement	9.9%
Market Average Movement	9.3%
10% most volatile stocks in AU Market	16.3%
10% least volatile stocks in AU Market	4.2%

Stable Share Price: IMU is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: IMU's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

Founded	Employees	CEO	Website
1986	n/a	Leslie Chong	https://www.imugene.com

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company’s HER-Vaxx is in Phase 1b/2 study for gastric cancer.

Imugene Fundamentals Summary

How do Imugene's earnings and revenue compare to its market cap?
IMU fundamental statistics
Market Cap	AU$1.20b
Earnings (TTM)	-AU$27.22m
Revenue (TTM)	AU$8.49m

134.5x

P/S Ratio

-41.9x

P/E Ratio

Is IMU overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMU income statement (TTM)
Revenue	AU$8.49m
Cost of Revenue	AU$0
Gross Profit	AU$8.49m
Other Expenses	AU$35.72m
Earnings	-AU$27.22m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0046
Gross Margin	100.00%
Net Profit Margin	-320.60%
Debt/Equity Ratio	0%

How did IMU perform over the long term?

See historical performance and comparison

New valuation analysis is now available for all ASX stocks. This is in beta.

Future Growth

How is Imugene forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

-1.3%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IMU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IMU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IMU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IMU's revenue (20.2% per year) is forecast to grow faster than the Australian market (4.8% per year).

High Growth Revenue: IMU's revenue (20.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: IMU is forecast to be unprofitable in 3 years.

Past Performance

How has Imugene performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-44.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: IMU is currently unprofitable.

Growing Profit Margin: IMU is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: IMU is unprofitable, and losses have increased over the past 5 years at a rate of 44.6% per year.

Accelerating Growth: Unable to compare IMU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IMU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.7%).

Return on Equity

High ROE: IMU has a negative Return on Equity (-17.95%), as it is currently unprofitable.

Financial Health

How is Imugene's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: IMU's short term assets (A$125.3M) exceed its short term liabilities (A$6.7M).

Long Term Liabilities: IMU's short term assets (A$125.3M) exceed its long term liabilities (A$1.1M).

Debt to Equity History and Analysis

Debt Level: IMU is debt free.

Reducing Debt: IMU has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IMU has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: IMU has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 37.9% each year

Dividend

What is Imugene current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate IMU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IMU's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IMU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IMU's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as IMU has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.5yrs

Average management tenure

CEO

Leslie Chong

5.5yrs

Tenure

AU$789,284

Compensation

Ms. Leslie Chong serves as Non-Executive Director of Chimeric Therapeutics Limited since August 28, 2020. Ms. Chong has been the Chief Executive Officer of Imugene Limited since November 21, 2016. Ms. Chon...

CEO Compensation Analysis

Compensation vs Market: Leslie's total compensation ($USD557.96K) is below average for companies of similar size in the Australian market ($USD1.03M).

Compensation vs Earnings: Leslie's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: IMU's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.

Board Members

Experienced Board: IMU's board of directors are considered experienced (4.2 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 19.9%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/25 00:00
End of Day Share Price	2022/05/25 00:00
Earnings	2021/12/31
Annual Earnings	2021/06/30